Vaccination is the single most important preventive health measure available for domestic cats. A well-designed vaccination programme protects individual cats from life-threatening infectious diseases, contributes to herd immunity that shields vulnerable individuals who cannot be vaccinated, and prevents outbreaks in multi-cat settings. Yet vaccination is also an area of genuine complexity — different vaccines carry different evidence bases, protection is never absolute, and schedules must be adapted to individual circumstances.
This guide explains the recommended cat vaccination schedule, what each vaccine protects against, when to vaccinate, and how to think about your cat’s specific risk profile when deciding which vaccines are appropriate.
Core vs. Non-Core Vaccines: What Is the Difference?
Veterinary vaccination guidelines divide feline vaccines into two categories:
- Core vaccines are recommended for all cats regardless of lifestyle, geographic location, or risk level. They protect against diseases that are either widespread, severe, or pose a public health concern. Missing core vaccines represents a significant and avoidable risk.
- Non-core vaccines are recommended selectively based on the individual cat’s lifestyle, environment, and exposure risk. They are not universally necessary but may be strongly indicated for specific cats — for example, those in catteries, those with outdoor access, or those in geographic areas with high pathogen prevalence.
The classification of vaccines into core and non-core categories follows recommendations from the World Small Animal Veterinary Association (WSAVA) Vaccination Guidelines Group and regional veterinary bodies. Different regions may have slightly different recommendations depending on local disease prevalence.
Core Feline Vaccines
1. Feline Panleukopenia Virus (FPV)
Feline panleukopenia — also called feline distemper or feline parvovirus infection — is caused by a highly resistant parvovirus that causes severe, potentially fatal gastroenteritis and bone marrow suppression, resulting in panleukopenia (a dramatic fall in all white blood cell types). The virus can survive in the environment for over a year and is highly resistant to many common disinfectants.
The FPV vaccine is one of the most efficacious in all of veterinary medicine. Studies have demonstrated duration of immunity exceeding seven years following a completed primary course, and immunity may be lifelong in some cats. Despite this exceptional efficacy, the primary kitten course requires multiple doses to overcome interference from maternally derived antibodies.
2. Feline Herpesvirus Type 1 (FHV-1)
FHV-1 is a major cause of feline upper respiratory disease, producing rhinotracheitis, conjunctivitis, and — in chronic or recurrent infection — corneal ulceration and keratitis. Like all herpesviruses, FHV-1 establishes lifelong latency in the trigeminal ganglia and can reactivate during periods of stress or immunosuppression.
FHV-1 vaccination does not sterilise immunity — vaccinated cats can still become infected and establish latent infection. However, vaccination substantially reduces the severity of acute disease and reduces viral shedding during active episodes, thereby limiting spread to other cats. Duration of immunity is typically cited at one to three years and declines more rapidly than for FPV.
3. Feline Calicivirus (FCV)
FCV is the other primary cause of cat flu, additionally responsible for oral ulceration and — in virulent systemic strains — severe multi-organ disease with significant case fatality rates. Unlike FHV-1, FCV does not establish latency but maintains persistent infection in a large proportion of exposed cats.
FCV vaccination is complicated by the virus’s high genetic diversity and rapid mutation rate. Multiple antigenic variants circulate simultaneously, and no single vaccine strain confers protection against all field strains. Vaccination provides approximately 75% protection against clinical disease in most studies. Newer multivalent vaccines incorporating a broader range of strains offer improved coverage and are preferred in high-risk environments.
Core Vaccine Schedule
The following schedule is based on WSAVA 2016 guidelines and widely adopted regional adaptations. Individual practices may adjust timing based on local epidemiology, product licensing, maternal antibody considerations, and patient risk factors.
| Age / Timing | Vaccines | Notes |
| 6–8 weeks | FPV + FHV-1 + FCV (F3) | First dose. Some protocols start at 8 weeks. Indicated earlier in high-risk environments (shelters, catteries). |
| 10–12 weeks | FPV + FHV-1 + FCV (F3) | Second dose; 3–4 week interval from first dose. |
| 14–16 weeks | FPV + FHV-1 + FCV (F3) | Final kitten dose. Critical — must be given at or after 16 weeks to ensure at least one dose after maternal antibody wanes. |
| 12 months | FPV + FHV-1 + FCV (F3) | First adult booster, given 12 months after completing the kitten course. |
| Every 1–3 years | FHV-1 + FCV | Annual boosters in high-risk or multi-cat environments; triennial may be acceptable for low-risk indoor cats. |
| Every 3 years | FPV | Long duration of immunity. Triennial boosting is generally sufficient for most adult cats. |
Non-Core Feline Vaccines
Feline Leukemia Virus (FeLV)
FeLV is a retrovirus causing immunosuppression, anemia, and lymphoma. It spreads through close cat-to-cat contact involving saliva and is more prevalent in outdoor cats and those with access to cats of unknown health status. While classified as non-core by WSAVA, several regional guidelines recommend FeLV vaccination as core for all kittens, given the severity of infection and the difficulty of guaranteeing a strictly indoor lifestyle for the lifetime of the cat.
Primary vaccination involves two doses 3–4 weeks apart starting from 8–9 weeks of age, followed by a booster at 12 months. Ongoing vaccination is then assessed annually based on lifestyle and exposure risk. Testing for FeLV status before vaccination is recommended — vaccinating an already-infected cat provides no clinical benefit.
Chlamydia felis
Vaccination against Chlamydia felis is recommended for cats in multi-cat environments or catteries where infection has been documented. It is included in some combination F4 vaccines alongside the core antigens. The vaccine reduces the severity of clinical conjunctivitis significantly but does not fully prevent infection or shedding. Annual boosters are recommended in at-risk populations.
Bordetella bronchiseptica
A live intranasal vaccine is available in some countries for cats entering high-density environments such as shelters or boarding catteries. A single intranasal dose can be given from 4 weeks of age, with annual re-vaccination recommended for cats with continued risk exposure. Mild transient sneezing following intranasal vaccination is common and self-limiting.
Feline Immunodeficiency Virus (FIV)
FIV vaccines have been developed but their widespread use is complicated by a significant diagnostic problem: vaccinated cats become FIV antibody-positive on standard tests and cannot subsequently be distinguished from truly infected cats using routine serology. For this reason, FIV vaccination is not widely recommended outside specific high-risk scenarios, and vaccinated cats should be microchipped and their vaccination status permanently documented.
Special Considerations
Maternally Derived Antibody (MDA) Interference
Kittens receive passive immunity via colostrum in the first hours of life. These maternally derived antibodies can interfere with active immunisation — they neutralise vaccine antigens before the kitten’s own immune system can mount a response. The level and duration of MDA varies considerably between individual kittens, depending on the queen’s immune status and the amount of colostrum ingested.
MDA to FPV can persist until 16 weeks or beyond in some kittens. This is why the final kitten dose is given at or after 16 weeks — to ensure that at least one dose falls after MDA has waned. Kittens vaccinated only at 8 and 12 weeks may not be fully protected if MDA was still present at both earlier time points.
Adult Cats with Unknown Vaccination History
Adult cats with unknown or incomplete vaccination histories should be treated as unvaccinated. A primary course of two doses 3–4 weeks apart is recommended for all core vaccines, followed by a 12-month booster. Serological testing to assess pre-existing immunity is an option but is rarely cost-effective compared to simply repeating the primary course, which is safe even in cats with existing immunity.
Vaccination in Catteries and Shelters
In high-density environments, vaccination schedules may be accelerated. Some protocols begin at 6 weeks with doses every 2–3 weeks until 16 weeks. Intranasal FHV-1 and FCV vaccines provide faster onset of local mucosal immunity than injectable vaccines and may be preferred at the point of intake in shelter settings. Mild self-limiting sneezing or nasal discharge in the days following intranasal vaccination is expected and does not indicate failure.
Vaccination During Pregnancy or Lactation
Modified live vaccines (MLVs) — which contain live attenuated organisms — should generally be avoided in pregnant queens due to the theoretical risk of foetal infection or reproductive complications. Killed (inactivated) vaccines are preferred when vaccination during pregnancy cannot be deferred. Ideally, queens should complete their booster vaccination at least two to four weeks before mating to ensure adequate antibody levels for colostral transfer.
Feline Injection Site Sarcoma (FISS)
Feline injection site sarcoma is a rare but serious malignant tumour that can develop at vaccination sites in cats. Its precise pathogenesis is not fully understood but appears related to persistent local inflammation at the injection site. To minimise risk and facilitate early detection, the WSAVA and the Vaccine-Associated Feline Sarcoma Task Force recommend the following:
- Use the lowest effective vaccination frequency supported by duration-of-immunity evidence
- Administer FeLV vaccine in the right rear leg (distal to the stifle where possible)
- Administer FCV/FHV-1/FPV vaccine in the right shoulder region
- Monitor all injection sites: any swelling persisting beyond 4 weeks, exceeding 2 cm in diameter, or growing after 4 weeks warrants immediate biopsy
The existence of FISS risk supports thoughtful, evidence-based vaccination scheduling — but it is not a reason to forgo vaccination against potentially fatal diseases. In all but the very lowest-risk situations, the benefits of vaccination substantially outweigh the risk of injection site reactions.
Frequently Asked Questions
Can indoor cats skip vaccination?
Indoor cats face significantly lower exposure risk for most pathogens, but their risk is not zero. FPV can be carried indoors on shoes, clothing, or equipment. FHV-1 and FCV can be contracted during veterinary visits, or if an indoor cat ever escapes or requires boarding. Core vaccination (FPV, FHV-1, FCV) is recommended for all cats. FeLV vaccination can be reviewed for genuinely low-risk indoor cats with no exposure to other cats.
Does my cat need a booster every year?
Not necessarily for all vaccine components. FPV has a long duration of immunity, and triennial boosting is appropriate for most adult cats in low-risk environments. FHV-1 and FCV boosters may be given annually in high-risk or multi-cat settings. For low-risk indoor cats, triennial boosting for all core components may be acceptable. The appropriate interval should be discussed with your veterinarian based on your cat’s specific circumstances.
My cat had a reaction last time — should I vaccinate again?
Mild transient reactions such as lethargy or localised soreness at the injection site are common and are not a contraindication to future vaccination. Systemic allergic reactions — anaphylaxis, facial oedema, persistent vomiting — are rare but warrant careful discussion with your veterinarian before the next vaccination. Pre-medication or alternative vaccine products may be considered. The decision to continue vaccinating must weigh the risk of the reaction against the risk of the disease being vaccinated against.
Are there alternatives to injection vaccines?
Intranasal and intraocular vaccines are available for FHV-1, FCV, and Bordetella bronchiseptica in some countries. These mucosal route vaccines provide faster onset of local immunity and avoid the injection site sarcoma risk associated with parenteral vaccines. They are particularly useful in shelter intake settings and for cats with a history of injection site reactions. Their immunity duration may differ from parenteral vaccines; consult product licensing information and your veterinarian.
Key Takeaways
- Core vaccines (FPV, FHV-1, FCV) are recommended for all cats and should be completed during kittenhood with a 12-month adult booster
- The final kitten dose must be given at or after 16 weeks to ensure at least one dose after maternally derived antibody has waned
- Non-core vaccines (FeLV, Chlamydia felis, Bordetella) are selected based on individual lifestyle and risk assessment
- Adult cats with unknown vaccination histories should receive a full primary course followed by a 12-month booster
- Injection site sarcoma risk supports evidence-based scheduling and correct anatomical site selection — not vaccination avoidance
- Vaccination frequency and vaccine selection should be reviewed with a veterinarian at least annually
References
1. Day MJ et al. (2016). WSAVA guidelines for the vaccination of dogs and cats. J Small Anim Pract 57(1):E1–E45.
2. Scherk MA et al. (2013). 2013 AAFP Feline Vaccination Advisory Panel Report. J Feline Med Surg 15(9):785–808.
3. Gore TC et al. (2006). Three-year duration of immunity in cats following vaccination against FRV, FCV, and FPV. Vet Ther 7(3):213–22.
4. Hartmann K et al. (2015). Efficacy of antiviral chemotherapy for feline herpesvirus-1. J Feline Med Surg 17(4):333–40.
5. Gobar GM, Kass PH (2002). World wide web-based survey of vaccination practices, postvaccinal reactions and vaccine site-associated sarcomas in cats. J Am Vet Med Assoc 220(10):1477–82.
6. August JR (2006). Consultations in Feline Internal Medicine, Vol. 5. Elsevier Saunders.